Home/Pipeline/High-Concentration / Subcutaneous Immunoglobulin

High-Concentration / Subcutaneous Immunoglobulin

Immunodeficiency, CIDP

ResearchEarly Development

Key Facts

Indication
Immunodeficiency, CIDP
Phase
Research
Status
Early Development
Company

About Tiantan Bio

Tiantan Bio's mission is to ensure the supply of safe, effective, and high-quality biological products for public health in China. Its key achievements include establishing one of the nation's most extensive plasma collection networks and a sophisticated manufacturing platform for blood products and vaccines, making it a market leader in its core segments. The company's strategy is centered on deepening its plasma fractionation capabilities, expanding its vaccine portfolio, and advancing a pipeline of novel biologics to address unmet medical needs. Its position within the Sinopharm system provides significant strategic advantages in regulatory alignment and public health procurement.

View full company profile